AC Immune Ltd (ACIU)vsMerck & Company Inc (MRK)
ACIU
AC Immune Ltd
$2.63
-1.87%
HEALTHCARE · Cap: $274.42M
MRK
Merck & Company Inc
$146.87
-0.19%
HEALTHCARE · Cap: $355.10B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 380099% more annual revenue ($66.57B vs $17.51M). MRK leads profitability with a 4.8% profit margin vs -246.5%. MRK earns a higher WallStSmart Score of 36/100 (F).
ACIU
Avoid24
out of 100
Grade: F
MRK
Hold36
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for ACIU.
Margin of Safety
-77.2%
Fair Value
$83.04
Current Price
$146.87
$63.83 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 1057.0% year-over-year
Conservative balance sheet, low leverage
Mega-cap, among the largest globally
Generating 4.5B in free cash flow
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -210.0% — below average capital efficiency
Trading at 8.6x book value
ROE of 7.6% — below average capital efficiency
4.8% margin — thin
Elevated debt levels
Comparative Analysis Report
WallStSmart ResearchBull Case : ACIU
The strongest argument for ACIU centers on Revenue Growth, Debt/Equity. Revenue growth of 1057.0% demonstrates continued momentum.
Bull Case : MRK
The strongest argument for MRK centers on Market Cap, Free Cash Flow.
Bear Case : ACIU
The primary concerns for ACIU are EPS Growth, Market Cap, Piotroski F-Score.
Bear Case : MRK
The primary concerns for MRK are Price/Book, Return on Equity, Profit Margin. A P/E of 116.1x leaves little room for execution misses. Thin 4.8% margins leave little buffer for downturns.
Key Dynamics to Monitor
ACIU profiles as a hypergrowth stock while MRK is a value play — different risk/reward profiles.
ACIU carries more volatility with a beta of 1.59 — expect wider price swings.
ACIU is growing revenue faster at 1057.0% — sustainability is the question.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
MRK scores higher overall (36/100 vs 24/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AC Immune Ltd
HEALTHCARE · BIOTECHNOLOGY · USA
AC Immune SA, a clinical-stage biopharmaceutical company, discovers, designs and develops drugs and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. The company is headquartered in Lausanne, Switzerland.
Visit Website →Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?